CD274 and neoplasm: In the KEYNOTE-024 trial involving patients with treatment-naïve advanced NSCLC with high PD-L1 expression on the surface of tumor cells and wild-type EGFR and ALK, pembrolizumab significantly improved progression-free survival (PFS), overall survival (OS), and the objective response rate (ORR)12.